CIRC-CARDIOVASC INTE 润色咨询

Circulation-Cardiovascular Interventions

出版年份：2008 年文章数：1276 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：4.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-28 衣谷

    结果中的重要文献是在结果体现，还是在引言中描述？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-28 msSSSSSD

    方法的撰写顺序/逻辑顺序是什么？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2018-12-11 唐小牛

    Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2018-12-11 唐小牛

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2018-11-19 pangshiwei

    瓣膜移植

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2017-07-16 13805560183

    赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2014-01-10 LCF3572

    好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1103661, encodeId=488111036612e, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103662, encodeId=c5fe110366214, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564284, encodeId=32855642844d, content=Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 是介入心脏病学领域一流刊物，确实还是很难中的，两者的IF多年来一直相当，近两年JACC Cardiovasc Interv在涨，Circ Cardiovasc Interv一直不变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:09:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564283, encodeId=b8a056428360, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：Circ Cardiovasc Interv 和 JACC Cardiovasc Interv 为介入心脏病学专业领域一流刊物，两者原来IF差不多，但近两年JACC Cardiovasc Interv一直在涨，前者一直7左右没变， 所在团队发生过两次Circ Interv不中转投 JACC interv很快中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fd31641245, createdName=唐小牛, createdTime=Tue Dec 11 10:03:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563353, encodeId=7b4f563353fa, content=瓣膜移植, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67ce42087, createdName=pangshiwei, createdTime=Mon Nov 19 00:00:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544335, encodeId=d71d54433530, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500594, encodeId=7b4e50059426, content=好文章可投CIRCULATION,编辑认为质量不错的话可能会直接转到某一子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=448, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f8f93556, createdName=LCF3572, createdTime=Fri Jan 10 23:33:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481410, encodeId=3bbd481410f4, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2011-06-29 medwu

    看涨哦，明年会不会再涨？

    0

共10条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分